All News

healthcare.costs_.jpg

Why Are Physicians Silent About Outrageous Drug Prices?

d MedPage Today

This article was written by Dr. Milton Packer, who wonders why physicians are struggling to get their priorities straight.

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
vaccine.jpg

Hold Myophenolate or Not with COVID-19 Vaccination?

d Jack Cush, MD

While the American College of Rheumatology recommends holding mycophenolate (MMF) in rheumatic and musculoskeletal diseases patients (RMD) receiving COVID-19 vaccines, there is limited data on such an approach. A recent cohort study of RMD patients showed that holding MMF yielded higher antibody responses than continuing MMF.

Read Article
World Health Organization has recommended baricitinib & sotrovimab for COVID-19 (both already given EUA by the FDA). BARI (+/- steroids) given as 4 mg qd to severe hospitalized COVID. Sotrovimab, is for outpt, less severe disease. https://t.co/Hv8YdWUoYk https://t.co/l98zcyfGRk https://t.co/RAHKhqPWjp

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA reports that between Dec 2020 and July 2021, COVID-19 vaccination saved nearly 241,000 lives, prevented 1, 133, 617 hospitalizations and prevented more than 14 million COVID-19 cases (all in 1st 6 mos of the COVID vaccines) https://t.co/VIcwcPwbjn

Links:

Dr. John Cush RheumNow ( View Tweet)

Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/Ef4b1fYwkw

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/VMEMLod8EP https://t.co/O6l5eLfFxo

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast! Dr. Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens. https://t.co/A2Kw7rtei6 https://t.co/U6tdmUkP73 https://t.co/Opo5cYc8UB

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: JAMA study shows that, compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia (HR 0.83; 95% CI, 0.67-1.02; P = .08). https://t.co/72P5EHwD8l

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Clinical trials generally fail in Sjögren's syndrome; but now a study shows that a biologic B cell inhibitor, ianalumab, met its primary endpoint with a dose-related decrease in disease activity (measured by ESSDAI) at week 24. https://t.co/o2b1kwZ9QG https://t.co/ayaDlpl7DI

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Patients on biologics are NOT at higher risk for COVID-19 infx. Retrospective matched cohort study compared 7631 Biologic Rx pts to 74910 matched cohort with equal Infx & death rates. COVID infx assoc w/ age, minorities, more comorbidities https://t.co/lY1MVpBoF1

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Duloxetine added to usual analgesics failed to improve pain in 132 hip or knee OA pts by WOMAC pain scores: 1) Dulox + usual care vs 2) Usual care showed no diff in pain at 3 mos or 12 mos. https://t.co/2luWWDYP81 https://t.co/KAmqlnofVv

Links:

Dr. John Cush RheumNow ( View Tweet)
New podcast! Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogrens. https://t.co/Pg4snhCZyo https://t.co/ruzRs0ypcn https://t.co/zwI8baPEcn

Links:

Dr. John Cush RheumNow ( View Tweet)
Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6

Links:

Dr. John Cush RheumNow ( View Tweet)
Hold Myophenolate or Not with COVID-19 Vaccination? https://t.co/9Bp8huqJ6M https://t.co/AD11BmoZE8

Links:

Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/MrywKZKcIV https://t.co/QgajVPdesg

Links:

Dr. John Cush RheumNow ( View Tweet)
Study 126 rheumatic disease (RMD) patients showed that post-vaccination flares of RMD are rare. Despite being on DMARDs, biologics, immunosuppressives, the rate of RMD reactivation was 0.007 person/mo. 5 mild articular flares in 3 women https://t.co/OWXWTedw3Q

Links:

Dr. John Cush RheumNow ( View Tweet)

Can PPI accelerate knee OA? UK cohort compared need for TKR in adults over 50yrs on PPI or H2 blockers. Those on omeprazole and pantoprazole had 21%-3& more TKR than H2B (but not elevated with lansoprazole, rabeprazole (HR=0.97) https://t.co/5TqFV3TpjG

Links:

Dr. John Cush RheumNow ( View Tweet)

FDA has approved an NGF inhibitor for arthritis in cats...yes CATS! Presumeably for OA, Solensia (frunevetmab) is a cat-specific MAb that binds nerve growth factor (NGF). In humans several NGF MAbs have failed (tanezumab in 2021) https://t.co/WcvXP8Bv21

Links:

Dr. John Cush RheumNow ( View Tweet)

KEEPSaKe-1 Trial in PsA - IL-23 Inhibition is Effective The KEEPSaKE-1 study in PsA has been published and shows that RIZ showed significant clinical improvements when given to active PsA patients who failed or were intolerant to ≥1 csDMARD. https://t.co/thYavd4dAR https://t.co/HnVtsrUgVB

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×